Please login to the form below

Not currently logged in
Email:
Password:

TNF blockers to carry cancer warning

Anti-inflammatory drugs known as TNF blockers are to carry stronger warnings about the increased risk of sometimes fatal cancer

Anti-inflammatory drugs known as tumour necrosis factor (TNF) blockers are to carry stronger warnings about the increased risk of sometimes fatal cancer in children and adolescents, the Food and Drug Administration (FDA) has said.

The decision concludes an investigation that began last year, in which the regulator examined a possible link between anti-TNF therapies and cancer. Analysis of reports of cancer in patients receiving the drugs showed that the increased risk occurred "after 30 months of treatment on average".

Around half of the cancers were lymphomas and some of the reported cancers were fatal, the FDA noted.

Revised prescribing information and updated boxed warnings will affect Johnson & Johnson's and Schering-Plough's Remicade (infliximab) and Simponi (golimumab); Amgen and Wyeth's Enbrel (etanercept); Abbott's Humira (adalimumab) and UCB's Cimzia (certolizumab).

The FDA has said it is working with the manufacturers to better determine the risk of cancer in children and adolescents who use the drugs, which are used to treat rheumatoid arthritis and the bowel ailment Crohn's disease, along with other inflammatory diseases.

5th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics